PTO/SB/30 (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. 10/821.723 Request Application Number For Filing Date April 8, 2004 Continued Examination (RCE) First Named Inventor Merry, et al. Transmittal Address to: Art Unit 1765 Mail Stop RCE Commissioner for Patents Examiner Name Patricia Ann George P.O. Box 1450 Alexandria, VA 22313-1450 Attorney Docket Number 8676/DISPLAY/AKT/RKK

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. Submission required under 37 C.F.R. 1.114 Note: If the RCE is proper, any previously filed unentered
amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).
a. Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.
Consider the arguments in the Appeal Brief or Reply Brief previously filed on Dither
b X Enclosed
i. ☐ Amendment/Reply iii. ☐ Information Disclosure Statement (IDS)
ii
2. Miscellaneous
 Suspension of action on the above-identified application is requested under 37 C.F.R. 1.103(c) for a period ofmonths. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. 1.17(i) required)
b. Other
3. Fees The RCE fee under 37 C.F.R. 1.17(e) is required by 37 C.F.R. 1.114 when the RCE is filed.
a. The Director is hereby authorized to charge the following fees, or credit any overpayments, to
Deposit Account No I have enclosed a duplicate copy of this sheet.
i. XRCE fee required under 37 C.F.R. 1.17(e)
ii. X Extension of time fee (37 C.F.R. 1.136 and 1.17)
iii.
b. Check in the amount of \$enclosed
c. Payment by credit card. The fee has been paid with the submission of this paper using the Patent Electronic
Business Center.
WARNING: Information on this form may become public. Credit card information should not be included on this form
WARNING. Information of the provide credit card information and authorization on PTO-2038.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED				
Signature	1/2/11	Date	February 16, 2007	
Name (Print /Type)	Keith Taboada, Esq.	Registration No.	45,150	

The collection of Information is required by 3T CFR, 1.14. The information is required to obtain or retains a benefit by the public which is to file (and by the INSTYO is processed, an application. Confidentially is governed by 30 U.S.C. 122 and 3T CRR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete the form and/or suggestrons for reducing this burset, should be set to the Chief Information Officer, U.S. Patient and Trademark Office, U.S. Expariment of Commence, P.O. Sox 1457, Association, should be set to the Information Officer, U.S. Patient and Trademark Officer, U.S. Patient Officer, U.S. Patient and Trademark Office

if you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.